Loading...
Regulatory considerations in oncologic biosimilar drug development
Biosimilar monoclonal antibodies are being developed globally for patients with different types of solid tumors and hematologic malignancies. Applications for proposed biosimilar monoclonal antibodies are being submitted to the regulatory authorities around the world and may increase patient access...
Na minha lista:
| Udgivet i: | MAbs |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Taylor & Francis
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4622730/ https://ncbi.nlm.nih.gov/pubmed/25961747 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1040973 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|